Wyeth has reported results for second quarter ended September 30, 2012.
The company’s net profit for the quarter declined by 10.90% at Rs 30.25 crore as compared to Rs 33.95 crore for the same quarter in the previous year. Total income of the company has increased by 5.35% at Rs 157.14 crore for quarter under review as compared to Rs 149.16 crore for the quarter ended September 30, 2011.
Wyeth is the Indian subsidiary of US-based Pharma Company Wyeth, a global leader in pharmaceutical, consumer healthcare and animal health products. The pharmaceuticals business of the company comprises bulk drugs and formulations, such as oral contraceptives, hormone replacement therapy, antibiotics, vaccines, steroids and other prescription medicines. The company also manufactures OTC pharmaceuticals, cosmetics, toiletries and other allied consumer products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1279.70 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2245.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: